Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
87 hedge funds and large institutions have $284M invested in Chinook Therapeutics, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 8 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 25
14% more call options, than puts
Call options by funds: $834K | Put options by funds: $734K
5% more capital invested
Capital invested by funds: $271M → $284M (+$13.7M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 89 → 87 (-2)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.66M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.33M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$1.71M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.49M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.21M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.96M |
| 3 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$1.19M |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
-$769K |
| 5 |
CF
Centaurus Financial
Anaheim,
California
|
-$516K |
KDNY Hedge Fund Activity: Q3 2018 in Review
87 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q3 2018, worth a combined $284M — up 5.1% from $271M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of KDNY and 6 opened new positions — a net loss of 2 holders — while 25 trimmed existing stakes and 36 added.
The largest buyer was BlackRock, adding an estimated $2.66M. The largest seller was Fidelity Investments, cutting an estimated $8.21M.
- 87 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q3 2018, down from 89 in Q2 2018.
- Funds reported $284M of Chinook Therapeutics, Inc. Common Stock stock for Q3 2018, up 5.1% quarter-over-quarter.
- 6 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q3 2018 and 8 closed out, a net change of -2 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q3 2018 was BlackRock, an estimated $2.66M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q3 2018 was Fidelity Investments, an estimated $8.21M sold.
Based on aggregated 13F filings for Q3 2018.